International Clinical Neuroscience Journal

Vol. 7 No. 4 (2020)

Neurotoxin Botulinum Inserts Apoptotic Effects on Certain Cancer Cell Lines Via Neural Niche of Tumors: A Molecular Study

International Clinical Neuroscience Journal, Vol. 7 No. 4 (2020), 28 September 2020 , Page 190-195

Abstract

Background: Background: Botulinum toxin A (BtxA) is a powerful neurotoxin reported to be effective as a cancer adjuvant therapy with fewer side effects. Previously we showed the apoptotic effects of BtxA on the GBM cell line (U87-MG). In order to confirm the positive neurotoxicity of BtxA on other cancer cell lines, including SK-OV-3, CHO, MCF-7, and PC-3, the present research has designed.
Methods: The cell lines prepared, cultured, and exposed to different concentrations of BtxA for 24 and 48 hours. Using MTT, Annexin V/PI assays and western blotting, cell viability, and apoptosis studied.
Results: Our results showed that different BtxA Botox concentrations led to significant cell death in each cell line in a dose-dependent manner (P < 0.001) but did not for PC-3 cells. The results of the Annexin V/PI staining indicated that BtxA induced apoptosis after 24 hours. The 1.45U, 1.75U, and 1.65U of BtxA respectively induced more than 50% apoptosis in MCF 7, SK-OV-3, and CHO cell lines. The results of caspase 3 showed more protein expression in the treated group compares to the control group.
Conclusion: BtxA, as a neurotoxin, can insert therapeutic anti-cancer and apoptotic effects on various types of cancerous cells; further studies need to illuminate the possible mechanisms.

Keywords:
  • BtxA neurotoxicity
  • Apoptosis
  • MCF-7
  • PC-3
  • SK-OV3
  • CHO cell lines

How to Cite

1.
Farhadi M, Jameie M, Derakhshanmehr B, Tahmasebi M, Soleimani M, Jameie SB. Neurotoxin Botulinum Inserts Apoptotic Effects on Certain Cancer Cell Lines Via Neural Niche of Tumors: A Molecular Study. Int Clin Neurosci J [Internet]. 2020 Sep. 28 [cited 2026 Jul. 25];7(4):190-5. Available from: https://journals.sbmu.ac.ir/neuroscience/article/view/32419

References

1. Zichel R, Mimran A, Keren A, Barnea A, Steinberger-Levy I, Marcus D, et al. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system. Clin Vaccine Immunol. 2010;17(5):784-92. doi: 10.1128/cvi.00496-09.
2. Peng Chen Z, Morris JG Jr, Rodriguez RL, Wagle Shukla A, Tapia-Núñez J, Okun MS. Emerging opportunities for serotypes of botulinum neurotoxins. Toxins (Basel). 2012;4(11):1196- 222. doi: 10.3390/toxins4111196.
3. Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun. 2008;76(3):1314-8. doi: 10.1128/ iai.01025-07.
4. Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol. 2008;622:79- 87. doi: 10.1007/978-0-387-68969-2_7.
5. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res. 2012;31(1):14. doi: 10.1186/1756-9966-31-14.
6. Arab M, Khayamzadeh M, Mohit M, Hosseini M, Anbiaee R, Tabatabaeefar M, et al. Survival of ovarian cancer in Iran: 2000-2004. Asian Pac J Cancer Prev. 2009;10(4):555-8.
7. Proietti S, Nardicchi V, Porena M, Giannantoni A. [Botulinum toxin type-A toxin activity on prostate cancer cell lines]. Urologia. 2012;79(2):135-41. doi: 10.5301/ru.2012.9254.
8. Truin W, Voogd AC, Vreugdenhil G, van der Heiden-van der Loo M, Siesling S, Roumen RM. Effect of adjuvant chemotherapy in postmenopausal patients with invasive ductal versus lobular breast cancer. Ann Oncol. 2012;23(11):2859- 65. doi: 10.1093/annonc/mds180.
9. Coarfa C, Florentin D, Putluri N, Ding Y, Au J, He D, et al. Influence of the neural microenvironment on prostate cancer. Prostate. 2018;78(2):128-39. doi: 10.1002/pros.23454.
10. Karsenty G, Rocha J, Chevalier S, Scarlata E, Andrieu C, Zouanat FZ, et al. Botulinum toxin type A inhibits the growth of LNCaP human prostate cancer cells in vitro and in vivo. Prostate. 2009;69(11):1143-50. doi: 10.1002/pros.20958.
11. Bandala C, Cortés-Algara AL, Mejía-Barradas CM, Ilizaliturri- Flores I, Dominguez-Rubio R, Bazán-Méndez CI, et al. Botulinum neurotoxin type A inhibits synaptic vesicle 2 expression in breast cancer cell lines. Int J Clin Exp Pathol. 2015;8(7):8411-8.
12. Gorgal T, Charrua A, Silva JF, Avelino A, Dinis P, Cruz F. Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type A injection. BMC Urol. 2012;12:1. doi: 10.1186/1471-2490-12-1.
13. Gabriel A, Champaneria MC, Maxwell GP. The efficacy of botulinum toxin A in post-mastectomy breast reconstruction: a pilot study. Aesthet Surg J. 2015;35(4):402-9. doi: 10.1093/ asj/sjv040.
14. Graham K, Unger E. Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018;13:6049-58. doi: 10.2147/ijn.s140462.
15. Oh SH, Lee Y, Seo YJ, Lee JH, Yang JD, Chung HY, et al. The potential effect of botulinum toxin type A on human dermal fibroblasts: an in vitro study. Dermatol Surg. 2012;38(10):1689- 94. doi: 10.1111/j.1524-4725.2012.02504.x.
16. Arunasree KM. Anti-proliferative effects of carvacrol on a human metastatic breast cancer cell line, MDA-MB 231. Phytomedicine. 2010;17(8-9):581-8. doi: 10.1016/j. phymed.2009.12.008.
17. Ansiaux R, Gallez B. Use of botulinum toxins in cancer therapy. Expert Opin Investig Drugs. 2007;16(2):209-18. doi: 10.1517/13543784.16.2.209.
  • Abstract Viewed: 515 times
  • PDF Downloaded: 439 times

Download Statastics